The Approval Process in Action

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.

Precious Metals Miner Extends First Majestic Loan
Source: Streetwise Reports (06/06/2025)

Sierra Madre Gold and Silver Ltd. (SM:TSX.V; SMDRF:OTCQX) extended a US$5M loan, enabling expansion at its silver-gold Guitarra mine in Mexico amid strong sector momentum. Read more to see how silvers supply crunch and new production gains could boost long-term value.

US Supplier Secures Lease on Drone Motor Production Plant
Source: Streetwise Reports (06/06/2025)

Unusual Machines Inc. (UMAC:NYSE.American) will be able to build at scale and produce smaller customized batches at this 17,000-square-foot manufacturing facility in Florida. Find out why two analysts rate this company Buy.

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports (06/06/2025)

PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.

Healthcare Firm Uncovers AI Healthcare Growth Opportunity
Source: Streetwise Reports (06/06/2025)

Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.

Canadian Biotech Advances High-Impact DDR Programs
Source: Streetwise Reports (06/06/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy.